Articles From: L'Oreal CEO Cuts Forecast for 2014 Cosmetics Market -- Report to La-Z-Boy Reports Fiscal 2015 First-Quarter Results; Increases Share Purchase Authorization


2014/9/9
French cosmetics company L'Oreal SA (OR.FR) expects the global cosmetics market to post slightly lower growth this year than previously expected after a disappointing summer, its Chief Executive is quoted as saying by French daily Le Figaro.
Sign-up for L'Oreal CEO Cuts Forecast for 2014 Cosmetics Market -- Report investment picks
2014/8/25
The Brand's Live Social Response Lab Will Empower Women To Be Their Own Beauty Expert And Create Red Carpet-Inspired Beauty Looks For Real Life Red Carpet Moments NEW YORK , Aug.
Sign-up for L'Oreal Paris Brings The Red Carpet To Women, In Real Time investment picks
2014/9/8
By Inti Landauro PARIS--French cosmetics giant L'Oreal (OR.FR) Monday said it had reached an agreement to buy Brazilian hair coloration company Niely Cosmeticos for an undisclosed price.
Sign-up for L'Oreal Signs Agreement to Buy Brazil's Niely Cosmeticos investment picks
Guidewire Software, Inc. (NYSE: GWRE) , a provider of software products to Property/Casualty (P/C) insurers, today announced that L’olivier Assurances , the French subsidiary of Admiral Group and an auto insurance provider, has selected Guidewire InsuranceSuite™ as its new platform for underwriting, policy administration, claims management, billing, rating, and client data management.
Sign-up for L’olivier Assurances Selects Guidewire Products for Underwriting, Policy Administration, Claims Management, and Billing investment picks
2014/6/27
HURRICANE, Utah , June 27, 2014 /PRNewswire/ -- L&G Auto Sales, located at 1490 W.
Sign-up for L&G Auto Sales Shifts Gears with the Addition of U-Haul Products and Services investment picks
La Caisse de dépôt et placement du Québec invests $200 million in WSP as part of the acquisition of Parsons Brinckerhoff Canada NewsWire MONTRÉAL, Sept.
Sign-up for La Caisse de dépôt et placement du Québec invests $200 million in WSP as part of the acquisition of Parsons Brinckerhoff investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced positive pre-clinical data for LJPC-1010 in non-alcoholic steatohepatitis (NASH). LJPC-1010 is a derivative of GCS-100, a carbohydrate inhibitor of galectin-3, which has shown activity in chronic kidney disease in a Phase 2 trial.
Sign-up for La Jolla Pharmaceutical Announces Positive Pre-Clinical Data for Oral Galectin-3 Inhibitor in Nonalcoholic Steatohepatitis (NASH) investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that the Company was added to the Russell Microcap Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indices on June 27.
Sign-up for La Jolla Pharmaceutical Company Added to the Russell Microcap Index investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the first patient has been enrolled in the Phase 1/2 clinical trial of LJPC-501 for the treatment of type 1 and type 2 hepatorenal syndrome (HRS). HRS is a life-threatening form of progressive renal failure in patients with liver cirrhosis or fulminant liver failure.
Sign-up for La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that the Company plans to begin a phase 3 registration program for LJPC-501 for the treatment of catecholamine-resistant hypotension (CRH), a new indication.
Sign-up for La Jolla Pharmaceutical Company Announces Planned Initiation of Phase 3 Registration Program for LJPC-501 in Resistant Hypotension investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the pricing of an underwritten offering of 4,800,000 shares of its common stock, offered at a price of $10.50 per share.
Sign-up for La Jolla Pharmaceutical Company Announces Pricing of Underwritten Offering of Common Stock investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement.
Sign-up for La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of Common Stock investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
Sign-up for La Jolla Pharmaceutical Company Announces Second Quarter and Year-to-Date 2014 Financial Results investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the closing of its underwritten public offering of 5,395,000 shares of common stock at a public offering price of $10.50 per share, which includes the partial exercise of the underwriters’ option to purchase up to an additional 720,000 shares of common stock.
Sign-up for La Jolla Pharmaceutical Company Closes Offering of Common Stock investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases today announced that it has signed an option agreement with Leland Stanford Junior University (“Stanford”) that will add proprietary technology to the Company’s programs.
Sign-up for La Jolla Pharmaceutical Company Enters into Agreement With Stanford University for New Drug Delivery Technology investment picks
La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a notice of allowance for patent application number 14/254,510 covering methods of treating chronic inflammation by intravenous administration of aqueous modified pectin solutions with molecular weights greater than 25 kilodaltons.
Sign-up for La Jolla Pharmaceutical Company Receives Notice of Allowance for Additional Patent Claims Covering Modified Pectin for the Treatment of Chronic Inflammation investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced the appointment of Robert H.
Sign-up for La Jolla Pharmaceutical Company Strengthens Board of Directors with Appointment of Robert H. Rosen investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 BIO International Convention, taking place June 23-26 in San Diego, California.
Sign-up for La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 BIO International Convention investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2014 Wedbush Securities Life Sciences Conference taking place August 12-13 in New York City.
Sign-up for La Jolla Pharmaceutical Company to Provide Corporate Overview at the 2014 Wedbush Securities Life Sciences Conference investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 9th Annual JMP Securities Healthcare Conference taking place June 24-25 in New York City.
Sign-up for La Jolla Pharmaceutical Company to Provide Corporate Overview at the 9th Annual JMP Securities Healthcare Conference investment picks
La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced that George Tidmarsh, M.D., Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference taking place September 8-10 in New York City.
Sign-up for La Jolla Pharmaceutical Company to Provide Corporate Overview at the Rodman & Renshaw 16th Annual Global Investment Conference investment picks
2014/8/12
Enters Two New Markets in Central America with Franchise Agreements in Nicaragua and Guatemala IRVING, Texas , Aug.
Sign-up for La Quinta Holdings Continues International Expansion investment picks
- Generated RevPAR Growth of 7.7% - Achieved Pro forma Adjusted EBITDA Growth of 13.1% - Increases Full Year 2014 Guidance IRVING, Texas , Aug.
Sign-up for La Quinta Holdings Reports Strong Second Quarter 2014 Results investment picks
2014/9/8
IRVING, Texas , Sept.
Sign-up for La Quinta Holdings To Participate In The Bank Of America Merrill Lynch 2014 Gaming And Lodging Conference investment picks
2014/7/21
IRVING, Texas , July 21, 2014 /PRNewswire/ -- La Quinta Holdings Inc. (the "Company") (NYSE: LQ) today announced that the Company will release financial results for the second quarter 2014 after the market closes on Tuesday, August 12, 2014 .
Sign-up for La Quinta Holdings To Report Second Quarter 2014 Earnings And Host Conference Call investment picks
MONROE, Mich.
Sign-up for La-Z-Boy Announces Fiscal 2015 First-Quarter Conference Call investment picks
MONROE, Mich.
Sign-up for La-Z-Boy Names Daniel King President Of Retail Segment investment picks
MONROE, Mich.
Sign-up for La-Z-Boy Reports Fiscal 2014 Year-End And Fourth-Quarter Results investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: L'Oreal CEO Cuts Forecast for 2014 Cosmetics Market -- Report to La-Z-Boy Reports Fiscal 2015 First-Quarter Results; Increases Share Purchase Authorization
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices